IDiyas

For the Inventor, By the Inventor

Shanghai, China

Dongbing Cui

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 9.1

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:

goldMedal7 out of 159 
 
Jiangsu Hengrui Medicine Company Ltd.
 patents
silverMedal7 out of 100 
 
Shanghai Hengrui Pharmaceutical Co., Ltd.
 patents
bronzeMedal3 out of 8 
 
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2019-2023

where 'Filed Patents' based on already Granted Patents

7 patents (USPTO):
1. 11780923 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2023-10-10),
2. 11717559 - Interleukin 15 protein complex and use thereof (2023-08-08),
3. 10905743 - Interleukin 15 protein complex (2021-02-02),
4. 10815304 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2020-10-27),
5. 10793643 - PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof (2020-10-06),
6. 10543284 - Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof (2020-01-28),
7. 10449250 - Anti-sclerostin antibody, antigen binding fragment and medical use thereof (2019-10-22),

Title: The Innovations of Dongbing Cui

Introduction

Dongbing Cui is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of medical science, particularly in the development of innovative therapies for cancer treatment. With a total of seven patents to his name, Cui's work has garnered attention for its potential impact on healthcare.

Latest Patents

One of Cui's latest patents is focused on a PD-L1 antibody, antigen-binding fragments, and their medical applications. This invention relates to the development of chimeric and humanized antibodies that include the CDR regions of the PD-L1 antibody. The pharmaceutical composition derived from this invention is aimed at treating PD-L1 mediated diseases or disorders, particularly as anti-cancer drugs. Another notable patent involves an interleukin 15 (IL-15) protein complex, which includes soluble fusion proteins designed for tumor therapy. This complex is engineered to form disulfide bonds, enhancing its therapeutic potential.

Career Highlights

Cui has worked with notable companies in the pharmaceutical industry, including Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.

Collaborations

Cui has collaborated with esteemed colleagues such as Weikang Tao and Lianshan Zhang. These partnerships have facilitated the advancement of his research and the successful development of his patents.

Conclusion

Dongbing Cui's contributions to medical innovation, particularly in cancer therapy, highlight his role as a leading inventor in the field. His patents reflect a commitment to improving healthcare through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…